Tvardi Therapeutics Q3 2026 Results: Net Loss of $6.12M, Loss Widens
Tvardi Therapeutics reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $10.9 million loss in the prior year period. The company strengthened its liquidity by raising $13.3 million through an at-the-market equity facility, ending the quarter with $22.3 million in cash and cash equivalents.
- Key figure
- Net loss $6.12M